Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« A Response From Sanofi | Main | Department of Lots of Nerve (Patent Applications Desk) »

March 5, 2012

Trouble With a Boron-Containing Drug Candidate

Email This Entry

Posted by Derek

There have been all kinds of boronic acid-based enzyme inhibitors over the years, but they've been mostly locked in the spacious closet labeled "tool compounds". That's as opposed to drugs. After all these years, Velcade is still the only marketed boron-containing drug that I know of.

There's been a good attempt to change that in antibacterials, with the development of what's commonly referred to as "GSK '052", short for GSK2251052. That's a compound that originally came from Anacor about ten years ago, then was picked up by GlaxoSmithKline, and it's an oxaborole heterocycle that inhibits leucyl tRNA synthetase. (Here's a review on that whole idea, if you're interested).
GSK%20052.png
Unfortunately, last month came word that the Phase II trial of the drug had been suspended. All that anyone's saying is that there's a "microbiological finding", which isn't too informative when it's applied to y'know, an antibacterial trial. (At least it doesn't sound like a general safety or tox problem, at any rate).

Anacor is continuing to exploit boron-containing compounds, although opinion looks divided about their prospects. I always have a sneaking fondness for odd compounds and elements, though, so I'd have to root for them just on that basis.

Comments (19) + TrackBacks (0) | Category: Infectious Diseases | Odd Elements in Drugs


COMMENTS

1. canchem on March 5, 2012 8:58 AM writes...

I had put forward a boron-containing candidate for an antibacterial program a couple of years ago. The higher-ups were suspicious, to say the least, but it was a single step synthesis from a stockpiled intermediate, so they let me try it out. Bugger had no activity... Oh well, c'est la vie.

Permalink to Comment

2. Curious Wavefunction on March 5, 2012 9:17 AM writes...

"Microbiological finding"? The bugs mopping it up and feeling even more energized? Or chopping it up and discarding it like last night's leftovers?

Permalink to Comment

3. SP on March 5, 2012 9:21 AM writes...

Maybe they started incorporating it into their DNA.

Permalink to Comment

4. eugene on March 5, 2012 9:24 AM writes...

Boron salts play a role in signalling between different bacteria (quorum sensing), so I could see it as playing a positive signalling role for some certain species. Maybe promoting the creation of a biofilm.

Permalink to Comment

5. anon2 on March 5, 2012 9:30 AM writes...

Like any individual development candidate in Phases 1 or 2, this compound was always a long-shot to be a successfully demonstrated effective & safe drug. And more to the point, how many new chemical classes have been approved for use by FDA in the past 20 years as an oral antibacterial? Not a good track record.

Permalink to Comment

6. monoceros4 on March 5, 2012 10:38 AM writes...

"After all these years, Velcade is still the only marketed boron-containing drug that I know of."

Doesn't boric acid count? (I know, I know.)

Permalink to Comment

7. luysii on March 5, 2012 11:40 AM writes...

I wouldn't call AL-2 a salt, but it is used as a quorum sensor by a wide variety of bacteria. It starts out innocently enough as 2 hydroxy, 3 keto 4 keto 1 pentanol, but then forms a bicyclic ketal containing a boron ester. For the structure see Nature vol. 415 p. 546 '02.

Permalink to Comment

8. KW's hairdresser on March 5, 2012 11:51 AM writes...

Derek,

Zhi Hong, who directs GSK's Infectious Disease unit, fired nearly the entire chemistry staff in the states a year ago ostentibly to provide funds for GSK '052's development whilst touting this
"breakthough" molecule. Ironic.

Permalink to Comment

9. Kyle on March 5, 2012 12:55 PM writes...

Not knowing anything about the drug industry, why exactly is boron specifically avoided?

Permalink to Comment

10. Anonymous on March 5, 2012 1:26 PM writes...

It sounds like there was resistance seen with the compound during therapy [3 of 30 patients had what sounds like post-therapy raised MICs]. Not really unexpected with an inhibitor of a single enzyme If they can go up in dosage, they may be able to retard resistance development.

Permalink to Comment

11. partial agonist on March 5, 2012 1:27 PM writes...

Kyle,

It has more to do with the issue of covalent target modification. When you see a boron, it is likely there to interact covalently with a suitably place biological nucleophile, such as a serine side chain.

Many pharma companies have a strong bias against covalantly-acting compounds for anything but acute therapy, for several reasons not explained well in a quick blog post. Quick synopsis: there are concerns with target specificity and with potential immune responses to a modified protein (that's not as much a concern when the interaction is covalent but reversible,as is the case here, however)

Permalink to Comment

12. gippgig on March 5, 2012 2:31 PM writes...

Boron has an unusual ability to exist in both 3-coordinate (B(OH)3) and 4-coordinate (B(OH)4-) complexes (including simultaneously in the same molecule (see borax)). This gives it a very complex chemistry that should have unique uses. This has nothing to do with drugs, but I'm intrigued by the possibility of it acting as an ion channel - consider a channel blocked by RRBOH. OH- could bind to the B from one side, then the OH originally attached to the B could be released from the other side. It would be a molecular turnstile. Anyone have any idea if anybody has considered this?

Permalink to Comment

13. Anonymous on March 5, 2012 5:55 PM writes...

Keep in mind that it was this molecule that was used by senior management at GSK (in public interviews) to justify them ignoring the recommendations from GSK scientists to also not invest in Sirtris when questioned in the press about all the science that turned out to be faulty. I forget which one (Vallance, Slaoui or Witty) but they said that their internal scientists also didn't want them to invest in this company (Anacor) either. They ignored their internal scientists in both cases. Fortunately, theirs no accountability in management so they can fail every time and still rake in the millions. Unbelievable.........

Permalink to Comment

14. Anonymous on March 5, 2012 8:12 PM writes...

sorry, it's 'there's no accountability'........sorry for the typo........

Permalink to Comment

15. noname on March 5, 2012 8:27 PM writes...

Boronic acids readily form boronate esters with the 1,2- and 1,3-diols of saccharides, such as those that coat the surface of mammalian cells..........

Permalink to Comment

16. luysii on March 5, 2012 10:04 PM writes...

Just wondering if anyone out there managed to figure out the actual structure of AL-2 just from the description I gave, without looking up the reference. If you haven't, give it a shot. #15 noname gives a useful clue

Permalink to Comment

17. eugene on March 6, 2012 6:12 AM writes...

luysii, AI-2 (not AL) is formed by the reaction of an organic molecule with a boronic salt, which does not necessarily invalidate my comment. Incidentally, the starting molecule is a good substrate to try for a current project, but I don't think I'll have time before we send out the publication.

Permalink to Comment

18. bosshogg on March 6, 2012 7:49 PM writes...

Damn...I still have a suitcase full of Boron elixirs to unload. Uh, step right up and get your deuterated-antimicrobial pills...

Permalink to Comment

19. anon2 on March 7, 2012 12:55 PM writes...

18, bosshogg:
Try selling your deuterated ""whatever for"" little pills to Concert.....

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
The Worst Seminar
Conference in Basel
Messed-Up Clinical Studies: A First-Hand Report
Pharma and Ebola
Lilly Steps In for AstraZeneca's Secretase Inhibitor
Update on Alnylam (And the Direction of Things to Come)
There Must Have Been Multiple Chances to Catch This
Weirdly, Tramadol Is Not a Natural Product After All